袁 非, 陳向武
(復(fù)旦大學(xué)附屬中山醫(yī)院眼科, 上海 200032)
氧誘導(dǎo)視網(wǎng)膜新生血管模型中基質(zhì)細(xì)胞衍生因子1的表達(dá)及機(jī)制研究*
袁 非△, 陳向武
(復(fù)旦大學(xué)附屬中山醫(yī)院眼科, 上海 200032)
目的觀察基質(zhì)細(xì)胞衍生因子1(SDF-1)在氧誘導(dǎo)視網(wǎng)膜新生血管(OIR)模型中的表達(dá)情況,并初步研究其在OIR模型中的促新生血管生長(zhǎng)機(jī)制。方法30只C57BL/6J新生小鼠隨機(jī)分為2組。其中15只小鼠置于氧濃度為75%的容器內(nèi)飼養(yǎng)5 d,再轉(zhuǎn)移至正??諝庀嘛曫B(yǎng)5 d,作為高氧誘導(dǎo)組;另15只小鼠一直在正??諝庵酗曫B(yǎng),作為正常對(duì)照組。免疫組織化學(xué)方法檢測(cè)視網(wǎng)膜SDF-1、CD14蛋白的定位及含量,real-time PCR法檢測(cè)視網(wǎng)膜SDF-1 mRNA的表達(dá)。結(jié)果與正常對(duì)照組相比,高氧誘導(dǎo)組突破視網(wǎng)膜內(nèi)界膜的內(nèi)皮細(xì)胞核數(shù)目明顯增多(P<0.01),血管分支減少,大血管擴(kuò)張、迂曲。兩組小鼠視網(wǎng)膜神經(jīng)上皮均可見(jiàn)SDF-1和CD14陽(yáng)性染色,但高氧誘導(dǎo)組的SDF-1和CD14含量明顯高于正常對(duì)照組(均P<0.01)。并且視網(wǎng)膜SDF-1與CD14的蛋白含量存在正相關(guān)(r=0.898,P<0.01)。視網(wǎng)膜SDF-1 mRNA表達(dá)在高氧誘導(dǎo)組也明顯高于正常對(duì)照組(P<0.01)。結(jié)論OIR模型小鼠視網(wǎng)膜SDF-1表達(dá)增高,其促新生血管功能可能與CD14+細(xì)胞有關(guān)。
模型,氧誘導(dǎo)視網(wǎng)膜新生血管; 基質(zhì)細(xì)胞衍生因子1; CD14
視網(wǎng)膜新生血管是多種疾病如早產(chǎn)兒視網(wǎng)膜病變(retinopathy of prematurity, ROP)、增殖性糖尿病視網(wǎng)膜病變(proliferating diabetic retinopathy, PDR)等發(fā)生的共同病理改變,其造成的滲出、出血和增生等一系列變化最終會(huì)導(dǎo)致視力喪失。基質(zhì)細(xì)胞衍生因子1(stromal cell-derived factor 1,SDF-1)是一類具有趨化活性的細(xì)胞因子[1],在新生血管的生成過(guò)程中起重要作用[2-4],但具體機(jī)制尚未明了。大量資料顯示循環(huán)中的CD14+細(xì)胞(主要包括內(nèi)皮祖細(xì)胞[5-7]和單核/巨噬細(xì)胞)能促進(jìn)新生血管的生長(zhǎng)[8-11]。由于SDF-1是CD14+細(xì)胞的高效趨化因子[12, 13],因此我們推測(cè)SDF-1的促新生血管能力是通過(guò)趨化循環(huán)中CD14+細(xì)胞到達(dá)缺血部位而發(fā)揮作用。本研究旨在了解氧誘導(dǎo)視網(wǎng)膜新生血管模型(oxygen-induced retinopathy,OIR)中SDF-1的表達(dá)情況,并通過(guò)視網(wǎng)膜SDF-1表達(dá)與CD14含量的相關(guān)研究來(lái)初步探討我們的推測(cè)。
1實(shí)驗(yàn)分組
由中國(guó)科學(xué)院上海實(shí)驗(yàn)動(dòng)物中心提供[許可證號(hào)為SCXK(滬)2007-0005]7 d C57BL/6J清潔級(jí)新生小鼠共30只,隨機(jī)將其分為2組:正常對(duì)照組(n=15)和高氧誘導(dǎo)組(n=15)。其中正常對(duì)照組小鼠于正常環(huán)境中飼養(yǎng)10 d至17 d。而高氧誘導(dǎo)組小鼠首先生活在密閉玻璃容器內(nèi)(容器內(nèi)氧濃度保持在75%±2%,氣體流量為1.5 L/min)5 d后,轉(zhuǎn)移到正常環(huán)境繼續(xù)生活5 d至17 d。
2設(shè)備和試劑
2.1儀器設(shè)備 氧氣分析儀(CY-12C)購(gòu)自浙江省建德市梅城電化分析儀器廠。顯微鏡(Leica DM1RB)、高速冷凍離心機(jī)(Beckman GS-15R Centrifuge 和Eppendorf Centrifuge 5417R)、紫外線分光光度計(jì) (UV-1601 Shimadau)、熒光定量PCR儀(ABI 7500型)由復(fù)旦大學(xué)附屬中山醫(yī)院中心實(shí)驗(yàn)室提供。
2.2試劑 ADP酶、4%多聚甲醛、Tris-馬來(lái)酸緩沖液(0.05 mol/L和0.2 mol/L,pH 7.2)、硝酸鉛、氯化鎂、硫化銨,均由復(fù)旦大學(xué)上海醫(yī)學(xué)院組胚實(shí)驗(yàn)室提供。氧氣(純度≥99.99%)與氮?dú)?純度≥99.8%),由復(fù)旦大學(xué)附屬中山醫(yī)院提供。堿石灰、75%乙醇、異丙醇、無(wú)水乙醇、氯仿,購(gòu)自上海五四化學(xué)試劑有限公司。Trizol試劑購(gòu)自Invitrogen。引物由上海生工合成。兔抗鼠SDF-1及兔抗鼠CD14 Ⅰ抗、羊抗兔Ⅱ抗、DAB均購(gòu)自武漢博士德生物工程有限公司。
3視網(wǎng)膜鋪片的制作及二磷酸腺苷酶(adenosinediphosphatase,ADP)酶染色
每組17 d齡小鼠各取3只(6眼),行乙醚吸入麻醉,解剖小鼠胸腔,充分暴露心臟,將灌注針頭刺入左心室的同時(shí)用顯微剪刀剪開(kāi)右心房,先用生理鹽水灌注約5分鐘,然后灌注4%多聚甲醛溶液約5 min。再摘除小鼠眼球固定于4%多聚甲醛溶液中,4 ℃過(guò)夜。之后在小鼠眼球的角膜緣后約1 mm沿角膜緣環(huán)行剪開(kāi),去除角膜,取出晶狀體,以視乳頭為中心作4-5個(gè)放射狀切開(kāi),盡可能清除鞏膜、脈絡(luò)膜和視網(wǎng)膜色素上皮層。將視網(wǎng)膜鋪片用Tris-馬來(lái)酸緩沖液(0.05 mol/L,pH7.2)沖洗數(shù)次后,于37 ℃反應(yīng)液(濃度為0.2 mol/L,pH7.2的Tris-馬來(lái)酸緩沖液中加入3 mmol/L硝酸鉛。6 mmol/L氯化鎂、1 g/L ADP)中反應(yīng)15 min。再用Tris-馬來(lái)酸緩沖液(0.05 mol/L,pH7.2)沖洗15 min×5次,然后10%硫化銨顯色反應(yīng)5 min。最后用Tris-馬來(lái)酸緩沖液(0.05 mol/L,pH7.2)沖洗,甘油明膠封片。
4眼球石蠟切片制作
每組17 d齡小鼠各取6只(12眼),乙醚吸入麻醉,解剖胸腔,充分暴露心臟,將灌注針頭刺入左心室的同時(shí)用顯微剪刀剪開(kāi)右心房,先用生理鹽水灌注約5 min,然后灌注4%多聚甲醛溶液約5 min。摘除小鼠眼球固定于4%多聚甲醛溶液中,4 ℃過(guò)夜后,進(jìn)行全層石蠟包埋,制作6 μm切片,方向平行于角膜至視乳頭的矢狀位平面,每張切片的眼環(huán)中角膜所占比例均不小于1/5且包括后極部視網(wǎng)膜。每個(gè)眼球制作10張切片,其中2張用于免疫組化染色(分別進(jìn)行SDF-1和CD14免疫組化染色),8張用于HE染色。
5病理切片觀察和視網(wǎng)膜新生血管計(jì)數(shù)方法
眼球石蠟切片進(jìn)行常規(guī)HE染色和中性樹(shù)膠封片后,2組各隨機(jī)抽取30張制作和染色良好的眼球切片,在Leica DM1RB顯微鏡下觀察并統(tǒng)計(jì)每張切片突破視網(wǎng)膜內(nèi)界膜的血管內(nèi)皮細(xì)胞核數(shù),不包括玻璃體腔內(nèi)其它與內(nèi)界膜無(wú)聯(lián)系的新生血管芽,比較2組差異。
6SDF-1、CD14視網(wǎng)膜免疫組織化學(xué)染色及圖像分析
每個(gè)眼球2張石蠟切片,分別行SDF-1和CD14的免疫組化染色。常規(guī)進(jìn)行SDF-1及CD14的免疫組化SABC法染色后,Leica DM1RB顯微鏡200倍下逐一拍攝切片并錄入電腦后,用ImagePro Plus準(zhǔn)確選取切片中視網(wǎng)膜部分(排除眼內(nèi)外其它組織以免測(cè)量誤差),即AOI(area of interest),測(cè)定其中積分吸光度值(integrated absorbance,IA)。計(jì)算單位視網(wǎng)膜面積的積分吸光度值,即IA/AOIIA。數(shù)據(jù)錄入SPSS 16.0,采用t檢驗(yàn)比較組間SDF-1(和CD14)的IA/AOIIA值差異,用Spearson法對(duì)SDF-1與CD14的IA/AOIIA值相關(guān)性進(jìn)行分析。
7熒光實(shí)時(shí)定量PCR檢測(cè)視網(wǎng)膜SDF-1mRNA含量
每組17 d齡小鼠各取6只(12眼)經(jīng)頸脫臼處死后立即取出雙眼眼球,迅速沿鋸齒緣環(huán)行剪除眼前節(jié),4 ℃生理鹽水中剝離視網(wǎng)膜,以同一小鼠的2個(gè)眼球的視網(wǎng)膜組織作為1個(gè)標(biāo)本,加入1 mL Trizol后組織勻漿。常規(guī)分離抽提RNA,紫外吸收法測(cè)定RNA純度,隨后逆轉(zhuǎn)錄合成cDNA。
運(yùn)用Primer Premier 5.0設(shè)計(jì)引物,SDF-1引物序列如下:上游5’-GCCAACGTCAAGCATCTGAA-3’,下游5’-TGCACACTTGTTGTCTGTTGTTGTTCT-3’。反應(yīng)為40個(gè)循環(huán)(95 ℃30 s;β-actin:60 ℃ 1 min;SDF-1:55 ℃ 30 s;72 ℃ 40 s)。
結(jié)果與計(jì)算:2-△Ct為目的基因的量通過(guò)內(nèi)均一化處理之后相對(duì)于參照基因的值,由機(jī)器自動(dòng)生成。但為了結(jié)果表示的需要,在2-△Ct值的基礎(chǔ)上均擴(kuò)大1×105倍。
8統(tǒng)計(jì)學(xué)處理
數(shù)據(jù)輸入SPSS 16.0統(tǒng)計(jì)學(xué)軟件進(jìn)行分析。用t檢驗(yàn)比較正常組和高氧組之間突破內(nèi)界膜新生血管芽數(shù)目、SDF-1的平均吸光度值(IA/AOIIA)和mRNA表達(dá)量(即2-△Ct×105)、CD14的平均吸光度值之間差異。用Spearson相關(guān)分析法分析2組眼球切片SDF-1與CD14平均吸光度值的相關(guān)性。
1OIR模型的建立情況
1.1HE染色 隨機(jī)抽取正常對(duì)照組和高氧誘導(dǎo)組各30張眼球HE染色切片于顯微鏡下觀察。正常對(duì)照組見(jiàn)圖1A,其神經(jīng)纖維層較薄,外叢狀層無(wú)血管,未見(jiàn)突破內(nèi)界膜的血管內(nèi)皮細(xì)胞 ;而高氧誘導(dǎo)組見(jiàn)圖1B,其神經(jīng)纖維層與內(nèi)界膜附近有大量的新生血管,并且血管內(nèi)皮細(xì)胞突破內(nèi)界膜,在視網(wǎng)膜前形成新生血管,圖片中黑色箭頭為突破內(nèi)界膜的血管內(nèi)皮細(xì)胞,白色箭頭為新生血管管腔。光鏡下正常對(duì)照組突破內(nèi)界膜的新生血管芽為0個(gè),高氧誘導(dǎo)組685個(gè)。正常對(duì)照組突破內(nèi)界膜的內(nèi)皮細(xì)胞核數(shù)與高氧誘導(dǎo)組比較都有顯著差異(P<0.01),表明OIR模型成功。
Figure 1. HE-stained sections of retina (×200). A:control group ; B:oxygen-induced group. Black arrows:the endotheliocyte nuclei of new vessels from retinal inner limiting membrane into the vitreous. White arrow: retinal neovascularization.
圖1視網(wǎng)膜HE染色圖
1.2視網(wǎng)膜鋪片 正常對(duì)照組和高氧誘導(dǎo)組小鼠的視網(wǎng)膜鋪片經(jīng)過(guò)ADP酶染色后,置于光鏡下觀察視網(wǎng)膜血管形態(tài),可見(jiàn)正常對(duì)照組視網(wǎng)膜血管發(fā)育完全成熟,自視盤(pán)向外周呈放射狀均勻分布,未見(jiàn)血管閉塞,見(jiàn)圖2A;高氧誘導(dǎo)組小鼠后極部視網(wǎng)膜見(jiàn)大片無(wú)灌注區(qū),血管分支減少,大血管擴(kuò)張、迂曲,中周部大量新生血管形成,見(jiàn)圖2B,也表明OIR模型成功。
2視網(wǎng)膜神經(jīng)上皮SDF-1、CD14定位及半定量圖像分析
SDF-1免疫組化染色見(jiàn)2組視網(wǎng)膜切片均有棕黃色顆粒形成,主要分布于內(nèi)層視網(wǎng)膜(以內(nèi)顆粒層及神經(jīng)節(jié)細(xì)胞層最為明顯),部分血管周?chē)?xì)胞也可見(jiàn)明顯陽(yáng)性染色。CD14免疫組化染色表現(xiàn)同SDF-1。但需要注意的是CD14與SDF-1的陽(yáng)性染色顆粒在視網(wǎng)膜上分布的層次相同。另外高氧誘導(dǎo)組SDF-1、CD14免疫組化染色的棕黃色顆粒較正常對(duì)照組顏色更深,分布范圍更大,見(jiàn)圖3。
通過(guò)半定量圖像分析,正常對(duì)照組SDF-1的IA/AOIIA為0.0451±0.0109;高氧誘導(dǎo)組SDF-1的IA/AOIIA為0.0779±0.0145。正常組與高氧組之間比較,差異顯著(P<0.01),見(jiàn)圖4A。正常對(duì)照組CD14的IA/AOIIA為0.0454±0.0085;高氧誘導(dǎo)組CD14的IA/AOIIA為0.1021±0.0106。正常組和高氧組之間比較,差異顯著(P<0.01),見(jiàn)圖4B。用Spearson相關(guān)分析法,SDF-1與CD14蛋白的IA/AOI值呈正相關(guān)(r=0.898,P<0.01),見(jiàn)圖4C。
Figure 2. ADPase-stained sections of retina(×100). A:control group ; B:oxygen-induced group.
圖2視網(wǎng)膜鋪片圖
Figure 3. Immunohistochemistry detection of SDF-1 and CD14(×200). A: SDF-1 staining of control group; B: SDF-1 staining of oxygen-induced group; C: CD14 staining of control group; D: CD14 staining of oxygen-induced group. GCL:ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer.
圖3SDF-1、CD14免疫組化染色圖
3視網(wǎng)膜SDF-1mRNA的相對(duì)含量
將各個(gè)樣品的目的基因和管家基因分別進(jìn)行real-time PCR反應(yīng)。高氧誘導(dǎo)組2-△Ct×105值為22.545±5.630;正常組為10.021±3.150,2組間差異顯著(P<0.01),見(jiàn)圖4D。
本實(shí)驗(yàn)證實(shí)了OIR模型視網(wǎng)膜中SDF-1的表達(dá)增加。在SDF-1 mRNA水平,我們利用熒光實(shí)時(shí)定量的方法發(fā)現(xiàn)OIR模型小鼠視網(wǎng)膜中mRNA含量較正常小鼠增加。在SDF-1蛋白表達(dá)水平,我們利用免疫組化的方法,證實(shí)OIR模型視網(wǎng)膜SDF-1的表達(dá)以內(nèi)層為主;且高氧滲導(dǎo)組SDF-1較正常對(duì)照組顏色更深、范圍更廣;同時(shí)結(jié)合數(shù)字圖像分析系統(tǒng),用單位視網(wǎng)膜面積內(nèi)的陽(yáng)性表達(dá)累積吸光度作比較,進(jìn)行了半定量分析,我們可以證實(shí)該蛋白在OIR模型中視網(wǎng)膜組織表達(dá)明顯增加。
Figure 4. Graphs of the content and correlation of SDF-1 and CD14. A:scatter plot of SDF-1IA/AOIIA; B: scatter plot of CD14IA/AOIIA; C:scatter plot of collection between SDF-1 and CD14;D: scatter plot of SDF-1 mRNA expression.
圖4SDF-1與CD14的含量及其相關(guān)圖
近年SDF-1(CXCRL12)/CXCR4軸參與體內(nèi)新生血管生成的作用逐漸受到重視。Butler等[14]在缺血缺氧視網(wǎng)膜動(dòng)物模型中發(fā)現(xiàn),動(dòng)物玻璃體內(nèi)注射SDF-1中和抗體后,即使有外源性血管內(nèi)皮生長(zhǎng)因子的存在,也無(wú)視網(wǎng)膜新生血管的發(fā)生。此外,體外視網(wǎng)膜內(nèi)皮細(xì)胞培養(yǎng)的結(jié)果還提示它可上調(diào)黏附分子(VCAM-1)的表達(dá),而下調(diào)密封蛋白(occluding)的表達(dá)[14]。VCAM-1可促進(jìn)CD14+細(xì)胞的附壁、游走,occludin減少可加重血視網(wǎng)膜內(nèi)屏障的損傷,這些都是促進(jìn)新生血管的重要因素。既往的研究通過(guò)細(xì)胞離體培養(yǎng)或者測(cè)定增生性視網(wǎng)膜病變患者玻璃體、血清中SDF-1濃度等方法來(lái)間接提示SDF-1在視網(wǎng)膜新生血管中作用[15, 16],我們?cè)趯?shí)驗(yàn)中直接觀察到OIR模型中視網(wǎng)膜內(nèi)層SDF-1的表達(dá)明顯增加,無(wú)疑進(jìn)一步提示該因子在視網(wǎng)膜新生血管發(fā)展中的地位,但SDF-1是通過(guò)何種具體機(jī)制而促進(jìn)視網(wǎng)膜新生血管的生長(zhǎng)?這還需要更多工作。
結(jié)合大量研究資料[10,11,17, 18],我們推測(cè)SDF-1的促新生血管能力是通過(guò)趨化循環(huán)中CD14+細(xì)胞(如內(nèi)皮祖細(xì)胞和單核/巨噬細(xì)胞)到達(dá)缺血部位而發(fā)揮作用。假如該推測(cè)正確,那么在SDF-1高表達(dá)部位應(yīng)該有更多CD14+細(xì)胞的聚集。我們前面的研究已發(fā)現(xiàn),OIR模型中視網(wǎng)膜SDF-1表達(dá)較正常視網(wǎng)膜明顯增加,那么CD14+細(xì)胞聚集是否也隨之增多?
我們的研究采用視網(wǎng)膜CD14免疫組化染色來(lái)反應(yīng)CD14+細(xì)胞聚集程度,初步探討其與SDF-1之間的關(guān)系。實(shí)驗(yàn)結(jié)果發(fā)現(xiàn):(1)無(wú)論是在正常對(duì)照組,還是高氧誘導(dǎo)組視網(wǎng)膜中均有SDF-1和CD14的陽(yáng)性染色,并且值得注意的是這2種蛋白的陽(yáng)性染色在視網(wǎng)膜分布層次相同;(2)視網(wǎng)膜CD14與SDF-1的IA/AOIIA值存在正相關(guān)。假如我們的推測(cè)成立,那么受趨化的CD14+細(xì)胞所在位置應(yīng)該與SDF-1表達(dá)部位相一致,并且SDF-1表達(dá)越高聚集的CD14+細(xì)胞越多。而上面兩個(gè)結(jié)果都很好地吻合我們的推測(cè)。但是根據(jù)這些研究就判定我們前面的推測(cè)成立證據(jù)尚嫌不足,初步研究結(jié)果僅僅提示了這種存在的可能性。SDF-1與CD14+細(xì)胞的確切聯(lián)系還需要進(jìn)一步的研究。
我們利用免疫組化的半定量和熒光實(shí)時(shí)定量RT-PCR技術(shù)從兩方面證實(shí),OIR模型中視網(wǎng)膜SDF-1的表達(dá)水平較正常老鼠明顯增加。對(duì)于其調(diào)控、應(yīng)答機(jī)制的進(jìn)一步研究,及其視網(wǎng)膜玻璃體濃度對(duì)比的動(dòng)態(tài)變化研究,都有助于闡明視網(wǎng)膜新生血管性疾病的發(fā)病機(jī)制。
[1] 王 曄,鄧宇斌,李 燕,等.綠色熒光蛋白標(biāo)記的骨髓間充質(zhì)干細(xì)胞在腦缺血大鼠體內(nèi)遷移的實(shí)驗(yàn)研究[J].中國(guó)病理生理雜志,2009,25(3):519-524.
[2] Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1[J]. Nat Med, 2004,10(8):858-864.
[3] Zemani F, Silvestre JS, Fauvel-Lafeve F, et al.Exvivopriming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential[J]. Arterioscler Thromb Vasc Biol, 2008,28(4):644-650.
[4] Yin Y, Zhao X, Fang Y, et al. SDF-1alpha involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice[J]. Cardiovasc Pathol, 2010,19(4):218-227.
[5] Rehman J, Li J, Orschell CM, et al. Peripheral blood“endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors[J]. Circulation, 2003,107(8):1164-1169.
[6] Gulati R, Jevremovic D, Peterson TE, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood[J]. Circ Res, 2003,93(11):1023-1025.
[7] Romagnani P, Annunziato F, Liotta F, et al. CD14+CD34lowcells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors[J]. Circ Res, 2005,97(4):314-322.
[8] Anghelina M, Krishnan P, Moldovan L, et al. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles[J]. Am J Pathol, 2006,168(2):529-541.
[9] Anghelina M, Krishnan P, Moldovan L, et al. Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization[J]. Stem Cells Dev, 2004,13(6):665-676.
[10]Suh W, Kim KL, Kim JM, et al. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization[J]. Stem Cells, 2005,23(10):1571-1578.
[11]Apte RS. Regulation of angiogenesis by macrophages[J]. Adv Exp Med Biol, 2010,664:15-19.
[12]Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)[J]. J Exp Med, 1996,184(3):1101-1109.
[13]Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+progenitors to peripheral blood[J]. J Exp Med, 1997,185(1):111-120.
[14]Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy[J]. J Clin Invest, 2005,115(1):86-93.
[15]Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone[J]. Arch Ophthalmol, 2004,122(12):1801-1807.
[16]Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2005,46(11):4295-4301.
[17]De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells[J]. Blood, 2004,104(12):3472-3482.
[18]Moldovan L, Moldovan NI. Role of monocytes and macrophages in angiogenesis[J]. EXS, 2005,94:127-146.
Expressionofstromalcell-derivedfactor1inretinaswithoxygen-inducedretinalneovascularization
YUAN Fei, CHEN Xiang-wu
(DepartmentofOphthalmology,ZhongshanHospital,FudanUniversity,Shanghai200032,China.E-mail:yuanfei07@yahoo.cn)
AIM: To observe the expression of stromal cell-derived factor 1(SDF-1) in oxygen-induced retinopathy (OIR) model.METHODSThirty C57BL/6J newborn mice were randomly divided into 2 groups: 15 mice in oxygen-induced group were exposed to 75% oxygen for 5 days and to room air for another 5 days to establish the model of OIR, and the other 15 mice were kept in room air as control group. The mRNA expression of SDF-1 was determined by real-time RT-PCR. Retinal proteins of SDF-1 and CD14 were determined by immunohistochemistry.RESULTSThe numbers of the endotheliocyte nuclei in new vessels extending from retina to vitrous were lower in control group than that in oxygen-induced group (P<0.01). Positive immunohistochemical staining for SDF-1 and CD14 was found in both group, and significant differences of SDF-1 and CD14 between oxygen-induced group and control group (bothP<0.01) were observed. A strong correlation of retinal content of CD14 with the expression of SDF-1 was found (r=0.898,P<0.01). The difference of SDF-1 mRNA expression between oxygen-induced group and control group (P<0.01) was significant.CONCLUSIONThe expression of SDF-1 is increased in the retinas of OIR mice. Involvement of CD14+cells is a possible mechanism of SDF-1 in promoting neovascularization.
Models, oxygen-induced retinal neovascularization; Stromal cell-derived factor 1; CD14
R363
A
10.3969/j.issn.1000-4718.2011.01.027
1000-4718(2011)01-0139-06
2010-09-19
2010-11-11
上海市科學(xué)技術(shù)委員會(huì)科研計(jì)劃資助項(xiàng)目 (No.074119510)
△通訊作者 Tel:021-64041990; E-mail:15921292463@qq.com